AdvanCell is developing therapies to treat cancers including: prostate, skin, pancreatic, breast, bladder, colorectal, kidney ...

In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.

Citi raised the firm’s price target on Exelixis (EXEL) to $45 from $38 and keeps a Buy rating on the shares following the Q4 report. The ...

The PSMA PET CT scan is designed for prostate cancer detection, while the DOTA PET CT scan aids in identifying neuroendocrine tumors (rare growths that develop in hormone-producing cells).

As we observe World Cancer Day today, let us look at some of the trends in cancer therapeutics expected to improve cancer ...

New statistics reveal that breast and cervical cancers are now the leading causes of death among South African women, ...

AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, today announced the successful completion of an oversubscribed US$112 million Series C financing.

While Pluvicto is marketed for metastatic castration-resistant prostate cancer (mCRPC), Lutathera is indicated for treating ...

AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, today announced the successful completion of an ...